Endocrinologia: efeitos da terapia combinada com metformina e agonistas do GLP-1 na redução do peso corporal em pacientes com diabetes tipo 2

Abstract

This article addressed the efficacy of the combined therapy with metformin and GLP-1 agonists in reducing body weight in patients with type 2 diabetes, a condition that presents challenges in glycemic control and weight management. Type 2 diabetes, often associated with obesity, requires therapeutic interventions that control blood glucose levels and promote weight loss, an indispensable factor for improving clinical outcomes. In this context, the central problem investigated was the efficacy of this combined therapy compared to the isolated use of each agent, particularly concerning weight reduction and glycemic control. The objectives of this study were to review the available scientific literature on the effects of the combined therapy, evaluate the mechanisms of action of each drug, and analyze the results obtained in terms of weight loss and glycemic control. The methodology adopted consisted of a literature review, which included the selection of randomized clinical trials, systematic reviews, and meta-analyses published in recognized databases such as PubMed and Cochrane Library. The inclusion criteria focused on studies that investigated patients with type 2 diabetes treated with the combination of metformin and GLP-1 agonists, while the exclusion criteria eliminated studies that did not present specific data on weight reduction. The results obtained indicated that the combined therapy resulted in greater weight reduction compared to the isolated use of the agents, in addition to providing more robust glycemic control and a favorable safety profile. These findings confirmed the efficacy and safety of the combined therapy, highlighting its relevance in the integrated management of type 2 diabetes. It was concluded that the combination of metformin and GLP-1 agonists is an effective therapeutic strategy for patients who require interventions that address both glycemic control and weight reduction, contributing to improved clinical outcomes and patients' quality of life.